BCL10 Polyclonal Antibody
Applications
Reactivity
| Overview | |
| Catalog # | bs-55023R |
| Product Name | BCL10 Polyclonal Antibody |
| Applications |
WB
|
| Reactivity | Human |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Rabbit |
| Source | Recombinant fusion protein containing a sequence corresponding to amino acids 1-233 of human BCL10 (NP_003912.1). |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C for 12 months. |
| Target | |
| Gene ID | 8915 |
| Swiss Prot | O95999 |
| Subcellular location | Cytoplasm, Cell membrane |
| Synonyms | BCL10;CARMEN;CIPER;CLAP;IMD37;c-E10;mE10 |
| Background | This gene was identified by its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. The protein encoded by this gene contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are thought to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy. Alternative splicing results in multiple transcript variants. |
| Application Dilution | |
| WB | 1:300-5000 |